Adolescents' use of nicotine replacement therapy for smoking cessation: predictors of compliance trajectories.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

This study aims to test whether different NRT compliance trajectories can be distinguished among adolescents, to test whether these trajectories can be predicted by demographic, smoking-related, and personality factors, and to examine abstinence rates for each trajectory.

Who Took Part

The abstract describes 265 adolescents taking part.

The age groups tagged for this paper are teenagers, both men and women.

During NRT treatment, adolescents filled out six online questionnaires in which they reported on the number of days they used the patches.

Predictors (i.e., demographic and smoking-related factors and personality characteristics) and end-of-treatment abstinence were also administered through these self-reports.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Therapeutic nicotine (patch, non-peptide) group a baseline to be compared against.

Latent class growth analysis (LCGA) was used to analyze compliance data by classifying individuals into similar growth trajectories.

What Was Measured

PubMed files the paper under topics including Administration, Cutaneous, Netherlands, Nicotine, Nicotinic Agonists, Patient Compliance, Personality and Regression Analysis.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 265 adolescents.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (Psychopharmacology), a journal based in Germany.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.